Fisher Asset Management LLC Has $179.72 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Fisher Asset Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE) by 226.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 6,209,907 shares of the biopharmaceutical company’s stock after acquiring an additional 4,309,076 shares during the quarter. Fisher Asset Management LLC’s holdings in Pfizer were worth $179,715,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $25,000. Gladius Capital Management LP boosted its stake in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer during the second quarter valued at about $29,000. Quarry LP acquired a new stake in shares of Pfizer during the second quarter valued at about $31,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the second quarter valued at about $34,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 2.0 %

Shares of Pfizer stock opened at $26.17 on Tuesday. The stock has a fifty day simple moving average of $28.13 and a 200 day simple moving average of $28.56. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a market capitalization of $148.31 billion, a P/E ratio of 35.37, a price-to-earnings-growth ratio of 0.82 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the prior year, the company posted ($0.17) earnings per share. Pfizer’s revenue was up 31.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.42%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on PFE shares. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Barclays lifted their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.